YVES JONGEN
Chief Research Officer and Managing Director, based in Louvain-la-Neuve, Belgium

Yves Jongen is Chief Research Officer for Ion Beam Applications. After founding IBA in 1986, he served as general manager and co-general manager of the company until March 2000, when he assumed his current role. Founded in Louvain-la-Neuve, Belgium, IBA has become a world leader in particle accelerator technology and its applications, particularly in medical imaging, cancer therapy and sterilization. Prior to founding IBA, Mr. Jongen served for 16 years as manager of the UCL Cyclotron Research Center, a multidisciplinary organization established by the Catholic University of Louvain-la-Neuve (UCL), with several cyclotrons for fundamental and applied research. He holds a dozen patents and is the author of approximately 200 publications in the particle accelerator field and their applications. Mr. Jongen graduated cum laude from UCL in 1970 as a civil engineer in electronics and earned an additional certificate in nuclear sciences. He has received the Georges Vanderlinden prize for science, awarded by the Belgium Royal Academy, for his work in physics and electricity, and shared the magazine Trends-Tendances “1997 Entrepreneur of the Year” honors for the French-speaking part of Belgium with the former CEO of IBA, Pierre Mottet. In 2013, Yves Jongen was also nominated to the European Inventor Awards by the European Patent Office for making Proton Therapy more accessible to patients worldwide.

OLIVIER LEGRAIN
Chief Executive Officer and Managing Director, based in Louvain-la-Neuve, Belgium

Olivier Legrain graduated in economics from the Free University of Brussels (ULB) in 1992. After four years as auditor with Didier Claes and Associates, he joined IBA SA in 1996 as Controller and was closely involved with the Company’s IPO in 1998. With the acquisition of Scanditronix Medical AB by IBA in 1998, Olivier became Chief Financial Officer and then Chairman and Chief Executive Officer of IBA’s dosimetry business. After having successfully led this business for two years, Olivier became President of IBA Molecular, the Group’s molecular imaging subsidiary in 2003.

Having presided over two of IBA’s key business segments, Olivier was asked to return to head office in 2011 as Chief Strategy Officer, focused on establishing IBA’s future company strategy. In May 2012, Olivier became Chief Executive Officer of the IBA Group and has since been instrumental in refocusing the business on proton therapy and maintaining the Company’s world leading position in this next generation treatment modality.
PIERRE MOTTET
Chairman of the Board, Louvain-la-Neuve, Belgium

Pierre Mottet, married with three children, has a Master degree in Business-Engineering from the Catholic University of Louvain (UCL). During three years, he worked as Sales Engineer at IBM and got the IBM Marketing Excellence Award in 1985 and 1986. In 1987, he joined IBA as Sales Director, one year after the creation of the company. As from 1997, he occupied the position of Chief Executive Officer, year during which he was awarded the ‘Manager of the Year’ title together with Yves Jongen, Founder of IBA. In May 2012, Olivier Legrain succeeded him as CEO when Pierre Mottet was elected Vice Chairman of the Board and Chairman in 2013. Besides IBA, Pierre Mottet is Chairman of Xylowatt (green energy) Board member of UWE (Union Wallonne des Entreprises – Union of Companies based in Wallonia), Agoria (Federation of Belgian Technoly Companies) and Telemis SA (medical imaging). He is also member of the Managing Committee of the FEB (Federation of Belgian Enterprises).